Crinetics Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Crinetics Pharmaceuticals, Inc. (CRNX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CRNX insiders buying or selling?
In the last 12 months, Crinetics Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 12 sales ($6.5M) — net selling of $6.5M. Since July 2018, Trabud has recorded 134 Form 4 filings for CRNX: 12 buys ($76.3M) and 122 sells ($95.1M).
Source: SEC EDGAR Form 4
Key Statistics (July 2018 – Jul 7, 2026)
Total Form 4 filings
134
SEC EDGAR
Insider filers
16
Insider buys (12)
$76.3M
Insider sells (122)
$95.1M
Insider sentiment
Net sellingNet insider flow of $18.7M in net selling since July 2018, and $6.5M in net selling over the last 12 months.
Recent CRNX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Coelho Rogerio Vivaldi | Director | Sale | 3.0K | $40.00 | $120.0K | SEC ↗ |
| Jun 18, 2026 | Stephanie Okey | Director | Sale | 6.9K | $35.67 | $246.1K | SEC ↗ |
| Apr 10, 2026 | Jeff E. Knight | Chief Dev. & Operating Officer | Sale | 85.2K | $40.10 | $3.4M | SEC ↗ |
| Mar 18, 2026 | Jeff E. Knight | Chief Operating Officer | Sale | 9.9K | $37.37 | $370.4K | SEC ↗ |
| Mar 18, 2026 | Stephen F. Betz | Chief Scientific Officer | Sale | 10.6K | $37.37 | $396.6K | SEC ↗ |
| Mar 18, 2026 | Struthers Richard Scott | President & CEO | Sale | 22.0K | $37.37 | $821.5K | SEC ↗ |
| Mar 13, 2026 | Coelho Rogerio Vivaldi | Director | Sale | 5.0K | $36.15 | $180.8K | SEC ↗ |
| Mar 4, 2026 | Stephanie Okey | Director | Sale | 3.0K | $39.67 | $119.0K | SEC ↗ |
| Mar 4, 2026 | Tobin Schilke | Chief Financial Officer | Sale | 6.7K | $39.67 | $266.3K | SEC ↗ |
| Jan 7, 2026 | Isabel Kalofonos | Chief Commercial Officer | Sale | 2.5K | $55.00 | $137.5K | SEC ↗ |
| Dec 3, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 5.0K | $45.02 | $225.1K | SEC ↗ |
| Nov 5, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 5.0K | $42.66 | $213.3K | SEC ↗ |
| Oct 3, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 5.0K | $41.81 | $209.1K | SEC ↗ |
| Sep 30, 2025 | Struthers Richard Scott | President & CEO | Sale | 4.0K | $45.00 | $180.0K | SEC ↗ |
| Sep 30, 2025 | Matthew K Fust | Director | Sale | 16.0K | $44.75 | $716.0K | SEC ↗ |
| Sep 4, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 5.0K | $32.10 | $160.5K | SEC ↗ |
| Aug 26, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 30.0K | $30.43 | $912.9K | SEC ↗ |
| Aug 21, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 6.5K | $29.18 | $189.4K | SEC ↗ |
| Jun 16, 2025 | Stephen F. Betz | Chief Scientific Officer | Sale | 97.5K | $32.23 | $3.1M | SEC ↗ |
| Mar 21, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 2.5K | $34.20 | $86.0K | SEC ↗ |
| Mar 21, 2025 | Jeff E. Knight | Chief Operating Officer | Sale | 7.2K | $34.20 | $245.0K | SEC ↗ |
| Mar 21, 2025 | Stephen F. Betz | Chief Scientific Officer | Sale | 5.8K | $34.20 | $197.4K | SEC ↗ |
| Mar 21, 2025 | Struthers Richard Scott | President & CEO | Sale | 17.3K | $34.20 | $593.0K | SEC ↗ |
| Feb 5, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 5.0K | $39.07 | $195.3K | SEC ↗ |
| Jan 7, 2025 | Dana Pizzuti | Chief Med and Dev Officer | Sale | 15.0K | $52.09 | $781.4K | SEC ↗ |
Showing the 25 most recent of 134 Form 4 filings for Crinetics Pharmaceuticals, Inc..
Most active CRNX insiders
- Stephen F. Betz46 filings
- Dana Pizzuti17 filings
- Struthers Richard Scott14 filings
- Matthew K Fust9 filings
- Jeff E. Knight8 filings
Ask anything about CRNX insider activity
Use Trabud's AI agent to query Crinetics Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me CRNX CEO purchases this year" or compare it against any other ticker.
Open the AI agentCRNX insider trading FAQ
Are Crinetics Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Crinetics Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 12 sales ($6.5M) — net selling of $6.5M. Since July 2018, Trabud has recorded 134 Form 4 filings for CRNX: 12 buys ($76.3M) and 122 sells ($95.1M). Over the full record that is net selling of $18.7M.
How many insiders trade CRNX stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Crinetics Pharmaceuticals, Inc.. The most recent filing was accepted on Jul 7, 2026.
Where does Trabud get CRNX insider trading data?
All CRNX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.